Skip to main content
Top
Published in: BMC Cancer 1/2024

Open Access 01-12-2024 | Metastasis | Research

Undifferentiated sarcomatoid carcinoma of the pancreas-a single-institution experience with 23 cases

Authors: Lei Feng, Xiaojuan Tang, Zhen You

Published in: BMC Cancer | Issue 1/2024

Login to get access

Abstract

Background

The clinical course and surgical outcomes of undifferentiated sarcomatoid carcinoma of the pancreas (USCP) remain poorly characterized owing to its rarity. This study aimed to describe the histology, clinicopathologic features, perioperative outcomes, and overall survival (OS) of 23 resected USCP patients.

Methods

We retrospectively described the histology, clinicopathologic features, perioperative outcomes and OS of patients who underwent pancreatectomy with a final diagnosis of USCP in a single institution.

Results

A total of 23 patients were included in this study. Twelve patients were male, the median age at diagnosis was 61.5 ± 13.0 years (range: 35–89). Patients with USCP had no specific symptoms and characteristic imaging findings. The R0 resection was achieved in 21 cases. The En bloc resection and reconstruction of mesenteric–portal axis was undertaken in 9 patients. There were no deaths attributed to perioperative complications in this study. The intraoperative tumor-draining lymph nodes (TDLNs) dissection was undergone in 14 patients. The 1-, 3- and 5-year survival rates were 43.5%, 4.8% and 4.8% in the whole study, the median survival was 9.0 months. Only 1 patient had survived more than 5 years and was still alive at last follow-up. The presence of distant metastasis (p = 0.004) and the presence of pathologically confirmed mesenteric–portal axis invasion (p = 0.007) was independently associated with poor OS.

Conclusions

USCP was a rare subgroup of pancreatic malignancies with a bleak prognosis. To make a diagnose of USCP by imaging was quite difficult because of the absence of specific manifestations. Accurate diagnosis depended on pathological biopsy, and the IHC profile of USCP was mainly characterized by co-expression of epithelial and mesenchymal markers. A large proportion of patients have an early demise, especially for patients with distant metastasis and pathologically confirmed mesenteric–portal axis invasion. Long-term survival after radical resection of USCPs remains rare.
Literature
1.
go back to reference Mizrahi JD, et al. Pancreat cancer Lancet. 2020;395(10242):2008–20. Mizrahi JD, et al. Pancreat cancer Lancet. 2020;395(10242):2008–20.
2.
go back to reference Siegel RL et al. Cancer Statistics, 2021. CA Cancer J Clin, 2021. 71(1): p. 7–33. Siegel RL et al. Cancer Statistics, 2021. CA Cancer J Clin, 2021. 71(1): p. 7–33.
3.
go back to reference Sarantis P, et al. Pancreatic ductal adenocarcinoma: treatment hurdles, tumor microenvironment and immunotherapy. World J Gastrointest Oncol. 2020;12(2):173–81.CrossRefPubMedPubMedCentral Sarantis P, et al. Pancreatic ductal adenocarcinoma: treatment hurdles, tumor microenvironment and immunotherapy. World J Gastrointest Oncol. 2020;12(2):173–81.CrossRefPubMedPubMedCentral
4.
go back to reference Nagtegaal ID, et al. The 2019 WHO classification of tumours of the digestive system. Histopathology. 2020;76(2):182–8.CrossRefPubMed Nagtegaal ID, et al. The 2019 WHO classification of tumours of the digestive system. Histopathology. 2020;76(2):182–8.CrossRefPubMed
5.
go back to reference Luchini C, Capelli P, Scarpa A. Pancreatic ductal adenocarcinoma and its variants. Surg Pathol Clin. 2016;9(4):547–60.CrossRefPubMed Luchini C, Capelli P, Scarpa A. Pancreatic ductal adenocarcinoma and its variants. Surg Pathol Clin. 2016;9(4):547–60.CrossRefPubMed
6.
go back to reference Bazzichetto C, et al. Morphologic and molecular Landscape of Pancreatic Cancer variants as the basis of new therapeutic strategies for Precision Oncology. Int J Mol Sci. 2020;21(22):8841.CrossRefPubMedPubMedCentral Bazzichetto C, et al. Morphologic and molecular Landscape of Pancreatic Cancer variants as the basis of new therapeutic strategies for Precision Oncology. Int J Mol Sci. 2020;21(22):8841.CrossRefPubMedPubMedCentral
7.
go back to reference Quezada-Marín JI, et al. Gastrointestinal tissue-based molecular biomarkers: a practical categorisation based on the 2019 World Health Organization classification of epithelial digestive tumours. Histopathology. 2020;77(3):340–50.CrossRefPubMed Quezada-Marín JI, et al. Gastrointestinal tissue-based molecular biomarkers: a practical categorisation based on the 2019 World Health Organization classification of epithelial digestive tumours. Histopathology. 2020;77(3):340–50.CrossRefPubMed
8.
go back to reference Mattiolo P, et al. Epithelial-mesenchymal transition in undifferentiated carcinoma of the pancreas with and without osteoclast-like giant cells. Virchows Arch. 2021;478(2):319–26.CrossRefPubMed Mattiolo P, et al. Epithelial-mesenchymal transition in undifferentiated carcinoma of the pancreas with and without osteoclast-like giant cells. Virchows Arch. 2021;478(2):319–26.CrossRefPubMed
9.
go back to reference Lawlor RT, et al. Prognostic role of high-Grade Tumor budding in pancreatic ductal adenocarcinoma: a systematic review and Meta-analysis with a focus on epithelial to mesenchymal transition. Cancers. 2019;11(1):113.CrossRefPubMedPubMedCentral Lawlor RT, et al. Prognostic role of high-Grade Tumor budding in pancreatic ductal adenocarcinoma: a systematic review and Meta-analysis with a focus on epithelial to mesenchymal transition. Cancers. 2019;11(1):113.CrossRefPubMedPubMedCentral
10.
go back to reference Safi SA, et al. Mesopancreatic excision for pancreatic ductal adenocarcinoma improves local disease control and survival. Pancreatology. 2021;21(4):787–95.CrossRefPubMed Safi SA, et al. Mesopancreatic excision for pancreatic ductal adenocarcinoma improves local disease control and survival. Pancreatology. 2021;21(4):787–95.CrossRefPubMed
11.
go back to reference Heidt DG, Burant C, Simeone DM. Total pancreatectomy: indications, operative technique, and postoperative sequelae. J Gastrointest Surg. 2007;11(2):209–16.CrossRefPubMed Heidt DG, Burant C, Simeone DM. Total pancreatectomy: indications, operative technique, and postoperative sequelae. J Gastrointest Surg. 2007;11(2):209–16.CrossRefPubMed
12.
go back to reference Japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer, 2011. 14(2): p. 101–12. Japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer, 2011. 14(2): p. 101–12.
13.
go back to reference Menon KV, et al. Impact of margin status on survival following pancreatoduodenectomy for cancer: the Leeds Pathology Protocol (LEEPP). HPB (Oxford). 2009;11(1):18–24.CrossRefPubMed Menon KV, et al. Impact of margin status on survival following pancreatoduodenectomy for cancer: the Leeds Pathology Protocol (LEEPP). HPB (Oxford). 2009;11(1):18–24.CrossRefPubMed
14.
go back to reference Edition S, Edge S, Byrd D. AJCC cancer staging manual. AJCC cancer staging manual; 2017. Edition S, Edge S, Byrd D. AJCC cancer staging manual. AJCC cancer staging manual; 2017.
15.
go back to reference Picozzi VJ, et al. Five-year actual overall survival in Resected Pancreatic Cancer: a contemporary single-Institution experience from a multidisciplinary perspective. Ann Surg Oncol. 2017;24(6):1722–30.CrossRefPubMed Picozzi VJ, et al. Five-year actual overall survival in Resected Pancreatic Cancer: a contemporary single-Institution experience from a multidisciplinary perspective. Ann Surg Oncol. 2017;24(6):1722–30.CrossRefPubMed
16.
go back to reference Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240(2):205–13.CrossRefPubMedPubMedCentral Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240(2):205–13.CrossRefPubMedPubMedCentral
17.
go back to reference Bockhorn M, et al. Borderline resectable pancreatic cancer: a consensus statement by the International Study Group of pancreatic surgery (ISGPS). Surgery. 2014;155(6):977–88.CrossRefPubMed Bockhorn M, et al. Borderline resectable pancreatic cancer: a consensus statement by the International Study Group of pancreatic surgery (ISGPS). Surgery. 2014;155(6):977–88.CrossRefPubMed
18.
go back to reference Kane JR, et al. Sarcomatoid (spindle cell) carcinoma of the pancreas: a case report and review of the literature. Oncol Lett. 2014;7(1):245–9.CrossRefPubMed Kane JR, et al. Sarcomatoid (spindle cell) carcinoma of the pancreas: a case report and review of the literature. Oncol Lett. 2014;7(1):245–9.CrossRefPubMed
19.
go back to reference Alguacil-Garcia A, Weiland LH. The histologic spectrum, prognosis, and histogenesis of the sarcomatoid carcinoma of the pancreas. Cancer. 1977;39(3):1181–9.CrossRefPubMed Alguacil-Garcia A, Weiland LH. The histologic spectrum, prognosis, and histogenesis of the sarcomatoid carcinoma of the pancreas. Cancer. 1977;39(3):1181–9.CrossRefPubMed
20.
go back to reference Paal E, et al. A clinicopathologic and immunohistochemical study of 35 anaplastic carcinomas of the pancreas with a review of the literature. Ann Diagn Pathol. 2001;5(3):129–40.CrossRefPubMed Paal E, et al. A clinicopathologic and immunohistochemical study of 35 anaplastic carcinomas of the pancreas with a review of the literature. Ann Diagn Pathol. 2001;5(3):129–40.CrossRefPubMed
21.
go back to reference Gkountakos A et al. Undifferentiated Sarcomatoid Carcinoma of the pancreas: from histology and Molecular Pathology to Precision Oncology. Int J Mol Sci, 2022. 23(3). Gkountakos A et al. Undifferentiated Sarcomatoid Carcinoma of the pancreas: from histology and Molecular Pathology to Precision Oncology. Int J Mol Sci, 2022. 23(3).
22.
go back to reference Park W, Chawla A, O’Reilly EM. Pancreat Cancer: Rev Jama. 2021;326(9):851–62. Park W, Chawla A, O’Reilly EM. Pancreat Cancer: Rev Jama. 2021;326(9):851–62.
23.
go back to reference Conroy T, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364(19):1817–25.CrossRefPubMed Conroy T, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364(19):1817–25.CrossRefPubMed
25.
go back to reference Shiihara M, et al. A comparison of the pathological types of undifferentiated carcinoma of the pancreas. Pancreas. 2020;49(2):230–5.CrossRefPubMed Shiihara M, et al. A comparison of the pathological types of undifferentiated carcinoma of the pancreas. Pancreas. 2020;49(2):230–5.CrossRefPubMed
29.
go back to reference Wells A, Yates C, Shepard CR. E-cadherin as an indicator of mesenchymal to epithelial reverting transitions during the metastatic seeding of disseminated carcinomas. Clin Exp Metastasis. 2008;25(6):621–8.CrossRefPubMedPubMedCentral Wells A, Yates C, Shepard CR. E-cadherin as an indicator of mesenchymal to epithelial reverting transitions during the metastatic seeding of disseminated carcinomas. Clin Exp Metastasis. 2008;25(6):621–8.CrossRefPubMedPubMedCentral
30.
go back to reference Onder TT, et al. Loss of E-cadherin promotes metastasis via multiple downstream transcriptional pathways. Cancer Res. 2008;68(10):3645–54.CrossRefPubMed Onder TT, et al. Loss of E-cadherin promotes metastasis via multiple downstream transcriptional pathways. Cancer Res. 2008;68(10):3645–54.CrossRefPubMed
31.
go back to reference Vergara D, et al. Translating epithelial mesenchymal transition markers into the clinic: novel insights from proteomics. EuPA Open Proteom. 2016;10:31–41.CrossRefPubMedPubMedCentral Vergara D, et al. Translating epithelial mesenchymal transition markers into the clinic: novel insights from proteomics. EuPA Open Proteom. 2016;10:31–41.CrossRefPubMedPubMedCentral
32.
go back to reference Wang J et al. Perineural Invasion and Associated Pain Transmission in Pancreatic Cancer. Cancers (Basel), 2021. 13(18). Wang J et al. Perineural Invasion and Associated Pain Transmission in Pancreatic Cancer. Cancers (Basel), 2021. 13(18).
33.
34.
go back to reference Uenishi T, et al. A pancreatic anaplastic carcinoma of spindle-cell form. Int J Pancreatol. 1999;26(3):201–4.CrossRefPubMed Uenishi T, et al. A pancreatic anaplastic carcinoma of spindle-cell form. Int J Pancreatol. 1999;26(3):201–4.CrossRefPubMed
35.
go back to reference Higashi M, Takao S, Sato E. Sarcomatoid carcinoma of the pancreas: a case report with immunohistochemical study. Pathol Int. 1999;49(5):453–6.CrossRefPubMed Higashi M, Takao S, Sato E. Sarcomatoid carcinoma of the pancreas: a case report with immunohistochemical study. Pathol Int. 1999;49(5):453–6.CrossRefPubMed
36.
go back to reference De la Riva S et al. Sarcomatoid carcinoma of the pancreas and congenital choledochal cyst Gastrointest Endosc, 2006. 64(6): p. 1005-6; discussion 1006. De la Riva S et al. Sarcomatoid carcinoma of the pancreas and congenital choledochal cyst Gastrointest Endosc, 2006. 64(6): p. 1005-6; discussion 1006.
37.
go back to reference Ramacciato G, et al. Pancreatectomy with Mesenteric and Portal Vein Resection for Borderline Resectable Pancreatic Cancer: Multicenter Study of 406 patients. Ann Surg Oncol. 2016;23(6):2028–37.CrossRefPubMed Ramacciato G, et al. Pancreatectomy with Mesenteric and Portal Vein Resection for Borderline Resectable Pancreatic Cancer: Multicenter Study of 406 patients. Ann Surg Oncol. 2016;23(6):2028–37.CrossRefPubMed
38.
39.
go back to reference Leonhardt CS et al. Prognostic relevance of the revised R status definition in pancreatic cancer: meta-analysis. BJS Open, 2022. 6(2). Leonhardt CS et al. Prognostic relevance of the revised R status definition in pancreatic cancer: meta-analysis. BJS Open, 2022. 6(2).
40.
go back to reference Grossberg AJ, et al. Multidisciplinary standards of care and recent progress in pancreatic ductal adenocarcinoma. CA Cancer J Clin. 2020;70(5):375–403.CrossRefPubMedPubMedCentral Grossberg AJ, et al. Multidisciplinary standards of care and recent progress in pancreatic ductal adenocarcinoma. CA Cancer J Clin. 2020;70(5):375–403.CrossRefPubMedPubMedCentral
Metadata
Title
Undifferentiated sarcomatoid carcinoma of the pancreas-a single-institution experience with 23 cases
Authors
Lei Feng
Xiaojuan Tang
Zhen You
Publication date
01-12-2024
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2024
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-024-11988-2

Other articles of this Issue 1/2024

BMC Cancer 1/2024 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine